GlassScriptPhysician profile
Jana Waters
NPI 1932638715
$8,294.00
in general payments reported to CMS, 2019-2025
25 companies · $2,740 in 2025
The $2,740 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $407 · 2022: $1,069 · 2023: $1,784 · 2024: $2,294 · 2025: $2,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,792 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,792.33 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,555.01 | 2021-2025 | Clareon, Rocklatan, Eysuvis |
| Biotissue Holdings INC. | $1,272.91 | 2023-2025 | |
| Abbvie INC. | $890.88 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Sun Pharmaceutical Industries INC. | $643.24 | 2022-2025 | Cequa, Xelpros |
| Rxsight INC | $618.74 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Bausch & Lomb Americas INC. | $399.84 | 2022-2025 | Miebo, Vyzulta, Lotemax Sm |
| Amgen INC. | $355.69 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $314.99 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $304.48 | 2023-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $231.68 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $208.17 | 2022-2025 | Dextenza |
| Sight Sciences, INC. | $162.11 | 2025 | Omni Surgical System, Tearcare System |
| Rayner Intraocular Lenses Limited | $150.55 | 2024 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Astellas Pharma US INC | $127.12 | 2024 | Izervay |
| Horizon Therapeutics Plc | $125.71 | 2023 | Tepezza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $125.00 | 2022 | |
| Apellis Pharmaceuticals, INC. | $124.99 | 2023 | Syfovre |
| Dompe US, INC. | $121.85 | 2024 | Oxervate |
| Aerie Pharmaceuticals, INC. | $109.75 | 2021 | |
| Nova Eye, INC. | $105.12 | 2025 | |
| Lensar, INC. | $101.16 | 2025 | Lensar Laser System |
| Glaukos Corporation | $96.09 | 2023-2025 | Radius, Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Thea Pharma INC. | $78.76 | 2023-2025 | Iyuzeh |
| Allergan, INC. | $52.00 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $18.16 | 2023 | Tecnis Iol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jana Waters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.